FDA recalls Cheerios, Nutella and more
Digest more
The FDA warned Corcept Therapeutics that it would face significant hurdles if it submitted its lead rare disease asset for ...
A massive multi-category product recall has been issued after a pest infestation discovery.
The FDA has approved a label update for an inhaled insulin indicated for adults with type 1 or type 2 diabetes, according to ...
The FDA accepted an application for ivonescimab with chemotherapy for patients with lung cancer driven by EGFR changes after ...
Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...
The FDA is currently reviewing Summit's PD-1/VEGF bispecific as part of a chemotherapy combo for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer.
Life Biosciences plans to begin human clinical trials of a cellular rejuvenation therapy in optic neuropathies after ...
The target action date for orforglipron is now April 10.
For companies developing digital health products, wearables, or software-enabled devices, FDA’s latest guidance updates ...
By Kamal Choudhury Jan 30 (Reuters) - Shares of Corcept Therapeutics fell 16% on Friday after a corrected "complete response letter" from the U.S. Food and Drug Administration showed the agency had ...
MedPage Today on MSN
FDA OKs More Eye Drops That Can Replace Reading Glasses
Once-daily carbachol/brimonidine tartrate significantly improves aging-related vision loss ...
The U.S. Food and Drug Administration (FDA) has granted Biogen’s investigational drug, litifilimab, Breakthrough Therapy Designation for the treatment of cutaneous lupus erythematosus (CLE).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results